Chimeric Antigen Receptor (CAR) T cell therapies for rhabdomyosarcoma

CAR T cell therapy for solid tumors is hampered by the availability of ideal targets, by the hostile tumor microenvironment that hinder tumor infiltration, suppress T cell activation and proliferation, and induce T cell exhaustion.

In this research project, we aim to address these different points for CAR T cell therapy of rhabdomyosarcoma.